{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:35:21Z","timestamp":1764333321059,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In this study, we aim to evaluate the treatment responses and prognostic characteristics of Myasthenia Gravis (MG) patients followed in a tertiary neuromuscular diseases center in Turkey.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred seventy four MG patients (between years 2011 and 2022) in Antalya, Turkey were diagnosed, and evaluated on a classification of MG was based on Myasthenia. Gravis Foundation of America (MGFA) clinical classification. Exclusion of other possible diseases in the differential diagnosis and support by beneficial response to treatment with acetylcholinesterase inhibitors were also taken into consideration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean age of participants was 54.86 (SD\u2009=\u200914.856; min-max\u2009=\u200922\u201384). Ninety (51.7%) were female. MG was more common in women under the age of 65 (58%) and in men over the age of 65 (64%). Generalized MG was seen in 75.3% of the patients. Anti-AChR positivities were detected in 52.3%, Anti-MuSK positivity in 4.6%, and seronegativity in 22.4%. Thymoma was detected in nearly 9.8% and thymectomy was performed in 28.7 percent. Most of the patients (57.5%) were using corticosteroids. Azathioprine was used by 39% and mycophenolate mofetil by 10.3% of patients. Mortality was higher and disease was more severe in late-onset (&amp;gt;50\u2009years) MG patients (especially in the COVID-19 pandemic). Eight patients (four women, four men, mean age 75.5\u2009years) died during follow-up. None of them died due to myasthenic worsening, two died due to malignancy and two due to infection. During the COVID pandemic, 16 patients (9.2%) had COVID infection. Four patients died due to COVID-19 infection, these four patients had serious comorbidities, and three of them were elderly (&amp;gt;75\u2009years).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, MG is more common in women between the ages of 20\u201340 and in men over the age of 65. The use of corticosteroids was more common under the age of 50, and the use of non-steroidal immunosuppressant agents was more common over the age of 50. Thymectomy is still an important supportive treatment approach in anti-AChR positive and seronegative generalized patients under 50\u2009years of age. IVIG and plasmapheresis are effective treatments during acute exacerbations and bridging periods of treatments. Specific treatments are needed especially for resistant group of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1176636","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T01:36:16Z","timestamp":1691112976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic and prognostic features in myasthenia gravis patients followed in a tertiary neuromuscular diseases center in Turkey"],"prefix":"10.3389","volume":"14","author":[{"given":"Aylin","family":"Yaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Kurtulu\u015f Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"year":"2022","author":"Beloor Suresh","key":"ref1"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.17712\/nsj.2019.3.20190011","article-title":"Clinical features and outcomes of patients with myasthenia gravis","volume":"24","author":"Alanazy","year":"2019","journal-title":"Neurosciences (Riyadh)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.36185\/2532-1900-038","article-title":"Myasthenia gravis: MuSK MG, late-onset MG and ocular MG","volume":"39","author":"Deymeer","year":"2020","journal-title":"Acta Myol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13760-018-0943-7","article-title":"Antibody profile may predict outcome in ocular myasthenia gravis","volume":"118","author":"Galassi","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","article-title":"Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"70","author":"Jaretzki","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s13760-023-02187-0","article-title":"Current management of myasthenia gravis in Belgium: a single-center experience","volume":"123","author":"Mercelis","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/mus.27120","article-title":"The Duke myasthenia gravis clinic registry: I. Description and demographics","volume":"63","author":"Sanders","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/mus.27331","article-title":"Gender differences in clinical outcomes in myasthenia gravis: a\u2009prospective cohort study","volume":"64","author":"Thomsen","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/WNL.0000000000003339","article-title":"Increased risk for clinical onset of myasthenia gravis during the postpartum period","volume":"87","author":"Boldingh","year":"2016","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jneuroim.2014.09.013","article-title":"Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy","volume":"276","author":"Skriapa","year":"2014","journal-title":"J Neuroimmunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2013a multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","article-title":"Clinical and immunological differences between early and late-onset myasthenia gravis in Japan","volume":"230","author":"Suzuki","year":"2011","journal-title":"J Neuroimmunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"474512","DOI":"10.4061\/2011\/474512","article-title":"Thymoma in myasthenia gravis: from diagnosis to treatment","volume":"2011","author":"Romi","year":"2011","journal-title":"Autoimmune Dis"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clineuro.2012.06.013","article-title":"The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis","volume":"115","author":"Nikolic","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2147\/ndt.s3309","article-title":"Mycophenolate mofetil for myasthenia gravis: a clear and present controversy","volume":"4","author":"Heatwole","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cort\u00e9s-Vicente","year":"2020","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/nsn.nsn_201_20","article-title":"Late-onset myasthenia gravis: is it a different clinical entity?","volume":"38","author":"Tireli","year":"2021","journal-title":"Neurol Sci Neurophysiol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.nmd.2020.08.355","article-title":"Mortality rates and causes of death in Swedish myasthenia gravis patients","volume":"30","author":"Westerberg","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp.64.1.78","article-title":"Mortality and survival in myasthenia gravis: a Danish population based study","volume":"64","author":"Christensen","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s41983-022-00516-3","article-title":"The relationship between myasthenia gravis and COVID-19: a systematic review","volume":"58","author":"Tugasworo","year":"2022","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000011669","article-title":"Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis","volume":"96","author":"Sol\u00e9","year":"2021","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and covid-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho","year":"2020","journal-title":"Front. Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1176636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T01:36:20Z","timestamp":1691112980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1176636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":37,"alternative-id":["10.3389\/fneur.2023.1176636"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1176636","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"article-number":"1176636"}}